Predictmedix AI Announces Closing of $405,500 Second Tranche with Strong Participation from German Family Offices

Rhea-AI Summary

Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the second tranche of its non-brokered private placement, raising $405,500 with significant participation from two German family offices. The company issued 20,275,000 units at $0.02 per unit.

Each unit comprises one common share and one purchase warrant, allowing holders to acquire an additional common share at $0.05 within 24 months. The company maintains the right to accelerate the warrant expiry if the stock's volume-weighted average trading price exceeds $0.10 for ten consecutive trading days on the CSE.

The securities issued are subject to a four-month and one-day statutory hold period, with a third and final tranche expected to close shortly.

Positive

• Successful fundraising of $405,500 strengthens company's financial position
• Strategic investment from German family offices indicates growing institutional confidence
• International expansion of investor base into European markets

Negative

• Significant dilution with 20,275,000 new units issued
• Low unit price of $0.02 suggests weak market valuation
• Additional dilution possible with warrant exercise at $0.05

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-powered health screening solutions, is pleased to announce the successful closing of the second tranche of its non-brokered private placement, raising total gross proceeds of $405,500. Notably, this tranche saw strong participation from two prominent German family offices, underscoring growing international confidence in Predictmedix’s AI-driven innovations.

The Company issued 20,275,000 units (“Units”) at a price of $0.02 per Unit, raising $405,500 in this tranche. Each Unit consists of one common share of Predictmedix and one common share purchase warrant. Each full warrant (“Warrant”) entitles the holder to acquire an additional common share at $0.05 per share for a period of 24 months. However, if the volume-weighted average trading price of Predictmedix’s common shares on the CSE exceeds $0.10 for ten consecutive trading days (starting four months and one day after closing), the Company reserves the right to accelerate the warrant expiry date to no less than 30 days from the date of notice.

This strong participation from German family offices is a validation of Predictmedix’s technology and market potential. This marks a turning point in institutional interest, as global investors, particularly from Europe, begin to recognize the impact of the Company’s AI-driven screening solutions. The involvement of institutional capital underscores increasing confidence in Predictmedix’s commercial strategy, scalability and the growing demand for AI-powered solutions across industries.

All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day from the date of issuance.

The company expects to close off the third and final tranche shortly.

To receive company news, please sign up for alerts at the bottom of the page link below: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. PredictmedixAI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319586575/en/

Dr. Rahul Kushwah, COO

rahul@predictmedix.com

(647) 889 6916

Source: Predictmedix AI Inc.

FAQ

What are the terms of Predictmedix AI's (PMEDF) second tranche private placement?

The second tranche raised $405,500 by issuing 20,275,000 units at $0.02 per unit, with each unit including one common share and one warrant exercisable at $0.05 for 24 months.

What is the warrant acceleration clause in PMEDF's private placement?

If shares trade above $0.10 for 10 consecutive days on the CSE, Predictmedix can accelerate warrant expiry to 30 days after notice.

How long is the hold period for PMEDF's private placement securities?

Securities issued in the private placement have a statutory hold period of four months and one day from issuance.

Who were the main investors in Predictmedix AI's (PMEDF) second tranche?

Two prominent German family offices were the main participants in the second tranche, showing growing international institutional interest.